Citizen Portal
Sign In

Committee reports bill to require Medicaid coverage of GLP‑1 obesity drugs after debate over costs

Senate Committee on Health and Welfare · April 15, 2026

Loading...

AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.

Summary

The Senate Health and Welfare committee reported SB 4‑33 (as amended) to require Louisiana Medicaid to cover GLP‑1 drugs for specified obesity criteria after LDH presented fiscal modeling and clinical groups urged coverage; the committee adopted amendments narrowing eligibility and tied implementation to appropriations.

The Senate Health and Welfare committee on Wednesday voted to report SB 4‑33, a bill to require Louisiana Medicaid to cover GLP‑1 drugs for certain obesity criteria, after hearing fiscal estimates from the Department of Health and multiple public witnesses urging coverage for treating obesity as a chronic disease.

Seth Cole, Medicaid director at the Department of Health (LDH), told the committee the bill’s initial gross expenditure estimates were about $189,000,000 for the first fiscal year and $296,000,000 for the second fiscal year across state general fund and federal spending. "We estimate, though, that ... the net expenditures would be about $7,000,000 for that first 6 months and ... $11,000,000 for that second fiscal year for 12 months," Cole said, noting modeling assumptions — about 145,000 eligible Medicaid adults with an estimated 17 percent initial uptake and roughly 40 percent retention among those who start the drugs.

LDH officials and witnesses described the modeling assumptions and tradeoffs. LDH emphasized high upfront costs and the role of manufacturer rebates and a federal pricing initiative that could reduce net state costs. A department spokesperson also noted that oral formulations due later this year could affect uptake and cost dynamics.

Clinical and advocacy witnesses urged the committee to expand access. Douglas Dunsavage of the American Diabetes Association said obesity is a major driver of chronic disease in Louisiana and called the measure a "smart fiscal and public health strategy." Dr. Katie Queen of the Louisiana Obesity Society told the committee a state task‑force report had estimated Medicaid spending related to obesity at about $2.1 billion annually and said covering medications could be a sound investment with potential long‑term savings.

Committee members pressed LDH on assumptions about savings to other health spending (for example, diabetes and cardiovascular disease), the expected uptake rate, and the risk the program could rapidly expand costs if not carefully restricted. In response, LDH offered an amendment that tightened BMI eligibility and made implementation subject to legislative appropriation.

The chair moved to report SB 4‑33 as amended; there were no recorded objections and the bill was reported to the next stage.

What happens next: The bill, as amended, will move forward in the legislative process; LDH and the committee will continue to refine cost estimates and implementation language ahead of floor consideration.